Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17250
Corporate User License Price USD 750
Corporate User License Price INR 51750
Site License Price USD 500
Site License Price INR 34500
Request a Quote

Report Title

Prothena Corp Plc (PRTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Prothena Corp Plc (PRTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Prothena Corp Plc (PRTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Prothena Corp Plc (PRTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Prothena Corp Plc (Prothena) is a clinical biotechnology company, which discovers, develops and markets novel medicines that are indicated for the treatment of diseases associated with neuroscience and orphan diseases. The company develops monoclonal antibodies directed specifically at disease-causing proteins. Its pipeline products include PRX002, that targets alpha -synuclein protein for the treatment of Parkinson's disease and other synucleinopathies; NEOD001, that targets the circulating soluble and deposited aggregated amyloid in the treatment of primary systemic amyloidosis; PRX004, indicated to clear the misfolded (toxic) forms of the TTR amyloid protein in Transthyretin amyloidosis (ATTR amyloidosis). Protena also develops several discovery-stage programs in collaboration with other pharmaceurtical companies for neurodegenerative or orphan diseases such as Alzheimer's disease (AD), ALECT2 amyloidosis, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Prothena is headquartered in Dublin, Ireland.

Prothena Corp Plc (PRTA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 12

MJFF Enters into Agreement with Prothena 14

Licensing Agreements 15

Roche Enters Into Licensing Agreement With Prothena 15

Equity Offering 17

Prothena Files Registration Statement for Public Offering of Shares 17

Prothena Raises USD155.3 Million in Public Offering of Shares 18

Prothena Raises USD137 Million in Public Offering of Shares 20

Prothena Raises USD122 Million in Public Offering of Shares 22

Prothena Completes Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD123 Million 24

Prothena Raises USD82.7 Million in Public Offering of Shares 26

Prothena Completes Public Offering Of Shares For USD 92 Million 28

Prothena Corp Plc-Key Competitors 30

Prothena Corp Plc-Key Employees 31

Prothena Corp Plc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Strategy And Business Planning 33

May 24, 2018: Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline 33

Financial Announcements 34

Aug 07, 2018: Prothena reports second quarter 2018 financial results and provides R&D update 34

May 08, 2018: Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update 36

Feb 14, 2018: Prothena Reports Fourth Quarter and Full Year 2017 Financial Results 38

Nov 07, 2017: Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update 40

Aug 08, 2017: Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update 42

May 09, 2017: Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update 44

Feb 14, 2017: Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update 46

Corporate Communications 48

Jun 25, 2018: Prothena Appoints Tran B. Nguyen As Chief Operating Officer 48

Feb 02, 2018: Prothena Announces Resignation of Sarah Noonberg As Chief Medical Officer 49

Jun 12, 2017: Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer 50

May 16, 2017: Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer 51

Clinical Trials 52

Jun 19, 2018: Prothena Announces Phase 1b Clinical Trial Results Of PRX002/RG7935 For Parkinson's Disease Published In JAMA Neurology 52

Jun 18, 2018: New immunotherapy could stop progression of Parkinson's disease 53

Sep 18, 2017: Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis 54

Aug 15, 2017: Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting 56

Jul 05, 2017: Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease 57

Jun 08, 2017: Anti-Alpha-Synuclein Antibody is a Potential Disease-Modifying Treatment for Parkinson's Disease 58

Apr 02, 2017: Clinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease 59

Mar 09, 2017: Results for Prothena's Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson's Disease to be Presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases 61

Appendix 63

Methodology 63

About GlobalData 63

Contact Us 63

Disclaimer 63

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Prothena Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Prothena Corp Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10

Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 12

MJFF Enters into Agreement with Prothena 14

Roche Enters Into Licensing Agreement With Prothena 15

Prothena Files Registration Statement for Public Offering of Shares 17

Prothena Raises USD155.3 Million in Public Offering of Shares 18

Prothena Raises USD137 Million in Public Offering of Shares 20

Prothena Raises USD122 Million in Public Offering of Shares 22

Prothena Completes Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD123 Million 24

Prothena Raises USD82.7 Million in Public Offering of Shares 26

Prothena Completes Public Offering Of Shares For USD 92 Million 28

Prothena Corp Plc, Key Competitors 30

Prothena Corp Plc, Key Employees 31

Prothena Corp Plc, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Prothena Corp Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person